Lipocine Inc
LPCN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$11.87M
Close$
$0.83
42.9% downside
Current Fair Value
42.9% downsideOvervalued by 42.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $11.87 Million |
|---|---|
| Enterprise Value | $7.21 Million |
| Earnings per Share | $-1.77 |
| Beta | 0.47 |
| Outstanding Shares | 8,216,988 |
Return
| Return on Equity | -54.45% |
|---|---|
| Return on Assets | -49.72% |
| Return on Invested Capital | 24.04% |
Valuation & Multiples
| P/E Ratio | -0.77 |
|---|---|
| PEG | -4.07 |
| Price to Sales | - |
| Price to Book Ratio | 0.73 |
| Enterprise Value to Revenue | 4.6 |
| Enterprise Value to EBIT | 1.38 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.44
Consensus analyst estimateRevenue Estimate
$162,500
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.39
Consensus analyst estimateRevenue Estimate
$159,500
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 36.29%▼ 9.60% |
|---|---|
| Total Invested | $7.63M▼ 69.37% |
| Investors Holding | 37▼ 9.00% |
About Lipocine Inc
CEO: Mahesh Patel
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, L...